Springe zum Hauptteil

Infektiologie

Unsere Arbeitgruppe befasst sich mit klinischen und epidemiologischen Aspekten (Risikofaktoren)  antibioseresistenter Infektionen und der Optimierung der anti-infektiven Therapie. Wir verfügen über Erfahrung mit “personalisierter Medizin bei nosokomialen Infektionen und empirischer Antibiotikatherapie.

Siehe den aktuellen Publikationsverzeichnis bei PubMed

Thematischer Schwerpunkt

Unser Hauptfokus liegt auf der Entwicklung von Strategien zum rationalen Einsatz von Antibiose (“Antimicrobial Stewardship”). Wissenschaftliche Schwerpunkte sind klinische und therapeutische Aspekte von bakteriellen Infektionen in immunsupprimierten Patienten und die Infektionskontrolle. Hierbei liegt ein besonderer Schwerpunkt auf methicillin-resistenten Staphylococcus aureus (MRSA) und MDR gram-negativen Bakterien. Das Bestreben ist, die Lebensbedingungen der Patienten zu optimieren. Aus diesem Grunde arbeiten wir an versciedenen Projekten, um durch “Personalisierte Medizin” und der Verbesserung ihrer Anwendung eine erfolgreiche Umsetzung im Alltag des Patienten zu erreichen.

In Zusammenarbeit mit dem CIDiC.

Leitung

Prof. Dr. Evelina Tacconelli

Sekretariat

Telefonnummer: 07071 29-83685

Faxnummer: 07071 29-25115

E-Mail-Adresse: evelina.tacconelli@med.uni-tuebingen.de

Publikationen: PubMed


Studienprotokolle

Ausgewählte Publikationen

  • Tacconelli E, Mazzaferri F, de Smet AM, Bragantini D, Eggimann P, Huttner BD, Kuijper EJ, Lucet JC, Mutters NT, Sanguinetti M, Schwaber MJ, Souli M, Torre-Cisneros J, Price JR, Rodríguez-Baño J. (2019). “ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers.” Clin Microbiol Infect. [Epub ahead of print]
  • Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, Sharland M, Rajendran NB, Rodríguez-Baño J; EPI-Net COMBACTE-MAGNET Group. (2018). “Surveillance for control of antimicrobial resistance.” Lancet Infect Dis 18(3): e99-e106.
  • Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. (2018). “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.” Lancet Infect Dis 18(3): 318-327.
  • Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. (2018). “Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.” Gastroenterology 155(5): 1372-1382.e1317.
  • Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, Tacconelli E. (2017). “Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis.” Lancet Infect Dis 17(9): 990-1001.
  • Tacconelli E, Autenrieth IB, Peschel A. (2017). “Fighting the enemy within.” Science 355(6326): 689-690.
  • Huttner A, Cacace M, d’Andrea L, Skevaki C, Otelea D, Pugliese F, Tacconelli E. (2017). “Inequality dynamics in the workplace among microbiologists and infectious disease specialists: a qualitative study in five European countries.” Clin Microbiol Infect 23(5): 332.e331-332.e333

Publikationsverzeichnis bei PubMed

Weiterführende Infromationen

COMBACTE-MAGNET/ EPI-Net
The objectives of this large European funded project are to increase the collective scientific knowledge about the distribution and determinants of serious bacterial infections in Europe, by coordinating and sharing data across ND4BB epidemiology studies and by engaging external data sources and stakeholders.

COMBACTE - MAGNET

EPI-NET

DRIVE-AB: Driving re-investment in R&D and responsible antibiotic use (completed)
Data from surveillance systems, antibiotic prescription databases, and published literature will generate estimations of the present burden of antibiotic resistance from both clinical and economic perspectives across varying socioeconomic backdrops.

Simulation models informed by these data as well as data from past and ongoing epidemics will estimate current future public health needs and impact related to AMR, again in diverse socioeconomic settings.

DRIVE - AB

DZIF Clinical Trial Unit
The DZIF Clinical Trial Unit provides a platform for clinical studies, focusing on health-care associated infections at DZIF and at international level. Thereby our aims are to derive evidence for unmet medical needs in Infectious Disease, develop educational events on prevention and treatment of health-care-associated infections and improve translational research.

DZIF ATHOS (Antibiotika-THerapie-Optimierungs-Studie
Multicentre study “Impact of reduced cephalosporin and fluoroquinolone use on infections due to third-generation cephalosporin-resistant enterobacteria (3GCREB)”.

In Tübingen the prevalence of 3 GCREB and VRE at hospital admission as well incidence of infections and colonisation of 3 GCREB, VRE and Clostridium difficile will be determined and antibiotic consumption data analysed.

DZIF SPEKTRUM
Multicentre clinical study „Multizentrische, prospektive Kohortenstudie zu Mikrobiota-definierten und klinischen Risikofaktoren für eine Kolonisierung mit Clostridium difficile und -assoziierte Erkrankung (CDAD) in Risikokollektiven“.

The objectives of the study are to characterize microbiota-defined, clinical (drugs, nutrition, medical conditions) and immunological risk factors for colonisation of Clostridium difficile or CDAD in risk collectives.

DZIF Spektrum

INCREMENT (ESCMID Study group for bloodstream infections)
The Increment project is a multinational effort aimed at providing observational data on antibiotic therapy of bloodstream infections caused by multidrug-resistant, emerging Enterobacteriacea

Neglected impact of age in RCT (ESCMID Study group for infection in elderly)
This project analyses the effect of age in RCT on bacterial infections (pneumonia and UTI) and antimicrobial resistant infections (MRSA).

SSTI- ESCMID. Prevalence of Staphylococcus aureus among patients presenting with skin and soft tissue infections: a multi-center pilot study in Europe
The objectives of this multi-center study are to evaluate the prevalence of MSSA, MRSA and Staphylococcus aureus PVL-positive strains in community-acquired SSTIs as well as to determine molecular characteristics of the isolated strains.

The DZIF Clinical Trial Unit provides a platform for clinical studies, focusing on health-care associated infections at DZIF and at international level. Thereby our aims are to derive evidence for unmet medical needs in Infectious Disease, develop educational events on prevention and treatment of health-care-associated infections and improve translational research.

Antimicrobial stewardship and resistance: A meta-analysis
Antibiotic stewardship should ensure effective treatment for patients with bacterial infections. By a systematic review and meta-analysis, we will determine the effectiveness of antimicrobial stewardship interventions that aim to reduce the incidence of antimicrobial resistant colonisation and/ or infections in hospital inpatients. The focus lies on multiresistant gram positive bacteria, multidrug resistant gram negative bacteria and Clostridium difficile.

STROBE-AMS
Recommendations to Optimise Reporting of Epidemiological Studies on Antimicrobial Resistance and Informing Improvement in Antimicrobial Stewardship Antimicrobial stewardship (AS) plays a pivotal role in controlling antimicrobial resistance spread among hospitalized patients, although available evidence mainly relies on non-experimental observational studies. Improving designing and reporting of these studies is critical to the application of findings to AS programmes. The implementation of the newly developed STROBE-AMS tool can be used for the study design of epidemiological studies and Antimicrobial Stewardship (AS) programme.

Gender differences in outpatient antibiotic prescribing
A systematic review and meta-analysis The overall drug prescribing in community shows a substantially difference between males and females that could not only be explained by the incidence of diseases between gender. The project includes a systematic review of the literature and, where appropriate, a meta-analysis of studies investigating prescriptions according to gender in the outpatients setting with a specific focus on different age categories and antibiotic classes.

Modelling the effect of selective digestive tract decontamination (SDD) against ESBL-producing Enterobacteriaceae on the rate of bloodstream infections (BSI) among neutropenic patients
SDD of patients colonized with ESBL-producing Enterobacteriaceae has demonstrated short-lived efficacy following administration of the decolonization regime. By a mathematical modeling, we assess whether and under which conditions, SDD can be an effective intervention method to reduce BSI among neutropenic patients in hematological wards and evaluate parameters to which the model-predicted results are more sensitive.

Finanzierung

Deutsches Zentrum für Infektionsforschung / Federal Ministry of Education and Research / Innovative Medicine Initiative /European Federation of Pharmaceutical Industries and Associations/ World Health Organization / Joint Programming initiative on Antimicrobial Resistance
Cookie Einstellungen
Bitte treffen Sie eine Auswahl um fortzufahren.
Weitere Informationen zu den Auswirkungen Ihrer Auswahl finden Sie unter Hilfe.
 
Um fortfahren zu können, müssen Sie eine Cookie-Auswahl treffen.

Cookies zulassen:
Wir setzen das Analysetool Google Analytics ein, um Besucher-Informationen wie z.B. Browser, Land, oder die Dauer, wie lange ein Benutzer auf unserer Seite verweilt, zu messen. Ihre IP-Adresse wird anonymisiert übertragen, die Verbindung zu Google ist verschlüsselt.

Nur notwendige Cookies zulassen:
Wir verzichten auf den Einsatz von Analysetools. Es werden jedoch technisch notwendige Cookies, die eine reibungslose Navigation und Nutzung der Webseite ermöglichen, gesetzt (beispielsweise den Zugang zum zugangsbeschränkten Bereich erlauben).

Sie können Ihre Cookie-Einstellung jederzeit auf der Seite Datenschutzerklärung ändern. Zum Impressum.

Zurück

Cookies zulassen Nur notwendige Cookies zulassen